Supernus (SUPN) Q2 2026 earnings review
Top-Line Acceleration Eclipsed by Transformative Merger and Margin Squeeze
Supernus delivered robust 32% YoY revenue growth in Q2 2026, driven by a successful ONAPGO supply restart and strong ZURZUVAE collaboration revenue. However, profitability paints a deteriorating picture: a $54.9M non-cash impairment charge for APOKYN forced a $58.0M GAAP operating loss. Even on an adjusted basis, operating earnings are reversing, falling to $31.2M from $40.9M a year ago due to swelling SG&A costs tied to the Biogen collaboration. These financial dynamics are immediately overshadowed by the announcement of an all-stock merger of equals with Indivior, completely shifting the thesis from a standalone pipeline story to complex, large-scale CNS integration.
🐂 Bull Case
ONAPGO sales accelerated to $13.5M in Q2 (up 60% sequentially from Q1), proving that the resumption of patient initiations successfully cleared backlogs and captured new demand. Regulatory filing for a crucial second supplier is on track for Q3 2026.
Management increased full-year 2026 revenue guidance to $860-$890M and adjusted operating earnings to $150-$180M, signaling confidence in the second-half momentum of the core growth portfolio.
🐻 Bear Case
Despite a 32% top-line surge, non-GAAP adjusted operating earnings fell 24% YoY. Rising SG&A costs associated with the ZURZUVAE launch are eating into the operating leverage generated by legacy replacements.
A sudden $54.9M intangible asset impairment charge for APOKYN indicates a faster-than-expected deterioration of the legacy Parkinson's drug, wiping out GAAP profitability for the quarter.
⚖️ Verdict: ⚪
Neutral. The core commercial portfolio (Qelbree, ONAPGO, ZURZUVAE) is executing well and accelerating top-line growth. However, the unexpected deterioration in operating margins and the complexity introduced by the Indivior merger create significant near-term execution risk.
Key Themes
Transformative Merger with Indivior
Supernus announced an all-stock merger of equals with Indivior. This instantly pivots the corporate strategy from incubating internal CNS assets to integrating a massive global organization focused heavily on opioid use disorder (OUD). While management touts the creation of a 'well-positioned CNS company with a unique profile of scale,' investors must now weigh significant M&A execution risks, overlapping SG&A rationalization, and potential distraction from the ongoing ONAPGO and ZURZUVAE launches.
ONAPGO Supply Constraints Resolved
The long-standing ONAPGO supply narrative is officially reversing into a growth driver. Sales surged to $13.5M in Q2 2026, a 60% sequential acceleration from Q1's $8.4M. With approximately 2,600 enrollment forms submitted since launch, the conversion rate to paid drug is materially improving. Management confirmed the regulatory submission for a second supplier is on track for Q3 2026, aiming for mid-2027 approval to permanently de-risk the supply chain.
ZURZUVAE Collaboration Ramping Swiftly
Collaboration revenue for ZURZUVAE reached $35.4M, accelerating from $27.6M in Q1 2026. Biogen reported U.S. sales increased 53% YoY, with prescriptions up 62%. The rapid market penetration validates the initial acquisition of Sage Therapeutics, transforming postpartum depression into a meaningful, recurring revenue stream.
Negative Operating Leverage
A specific contradiction to the company's 'new phase of accelerated growth' narrative lies in the P&L structure. Management raised full-year adjusted operating earnings guidance, but Q2 2026 adjusted operating earnings actually decelerated to $31.2M from $40.9M a year ago. Total SG&A spiked 43% YoY to $133.6M, severely outpacing the 32% revenue growth. The primary culprit is the shared commercialization costs with Biogen for ZURZUVAE, signaling that revenue scaling is coming at a steep, immediate cost.
Qelbree Volume Stabilizing the Base
Qelbree sales decelerated slightly to 15% YoY growth ($89.2M) compared to 20% in Q1, but it remains the bedrock of the commercial portfolio. Growth is purely volume-driven, with prescriptions up 17% overall and adult prescriptions up an impressive 25%. Expanding the prescriber base in the complex adult ADHD market continues to yield dividends.
APOKYN Franchise Impairment
The legacy Parkinson's disease treatment APOKYN suffered a severe reversal, triggering a $54.9M non-cash intangible asset impairment charge. Net sales for the product plummeted 51% YoY to just $6.3M. While ONAPGO is meant to replace this revenue in the broader PD portfolio, the abrupt write-down exposes the rapidly shrinking floor of the legacy asset base.
Pipeline Advancement into Next-Gen CNS
Beyond the commercial portfolio, Supernus is advancing specific novel assets. SPN-817 (AChE inhibitor for epilepsy) and SPN-820 (mTORC1 activator for depression) are progressing through Phase 2b trials. Notably, SPN-443, a novel stimulant for ADHD, will initiate Phase 1 trials in adult healthy volunteers in H2 2026, offering long-term lifecycle optionality to Qelbree.
Other KPIs
Accelerating significantly. Up 52% YoY, these four products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) now represent 80% of total Q2 revenue, completing the strategic transition away from legacy assets (Trokendi XR and Oxtellar XR).
Stable and strengthening. Increased from $308.7M at year-end 2025, driven entirely by robust cash generation from operations. This pristine balance sheet provides maximum flexibility as the company maneuvers through the upcoming Indivior integration.
Accelerating +141% YoY, serving as a high-margin revenue supplement driven by royalties on generic versions of legacy products and intellectual property licensing.
Guidance
Accelerating. Raised from previous guidance of $840 - $870 million. The midpoint ($875M) implies a ~21.7% YoY growth rate compared to FY25's $719 million, confirming strong commercial momentum in the back half of 2026.
Stable to slightly Accelerating. Raised from prior $140 - $170 million. The midpoint ($165M) implies ~4% YoY growth from FY25's $158.7M. This starkly underpaces the 21.7% implied revenue growth, confirming long-term margin compression tied to Biogen partnership scale-up.
Accelerating. The low end was raised from $45 million to $55 million. Given $21.9M achieved in H1 2026, the company implies generating $33.1M - $48.1M in H2 2026, a massive sequential leap reflecting total confidence in the cleared supply backlog.
Decelerating/Deteriorating. Downgraded severely from previous guidance of $0 - $30 million profit. This $50M swing is almost entirely attributable to the $54.9M non-cash impairment of the APOKYN intangible asset recognized in Q2.
Key Questions
Indivior Merger Synergies and Costs
With the Indivior merger announced, how should investors think about near-term transaction and integration costs? What specific SG&A synergies are modeled for the combined commercial footprint?
ZURZUVAE Partnership Economics
Collaboration revenues from ZURZUVAE are growing rapidly, but SG&A expenses are heavily compressing adjusted operating margins. At what revenue threshold does this collaboration cross over into positive operating leverage for Supernus?
ONAPGO Supply Contingency
Given that the second FDA-approved supplier for ONAPGO won't be online until mid-2027, how confident is management that the current sole supplier can fulfill the implied $33M+ second-half 2026 demand ramp without any disruptions?
APOKYN Terminal Value
Following the $54.9M impairment charge, what is the carrying value left for APOKYN? Should we expect this product to functionally phase out completely over the next 12-18 months as ONAPGO takes over?